Agios Reports Business Highlights and First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Agios Pharma (AGIO) PT Raised to $44 at RBC Capital
May 3, 2024 6:34 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Agios Pharma (NASDAQ: AGIO) to $44.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "Key update from the 1Q24 is the refining of ENERGIZE-T/TD readout timeline to 2Q24 (from mid-2024), which... More
